A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

被引:128
|
作者
Clark, WM
Wechsler, LR
Sabounjian, LA
Schwiderski, UE
机构
[1] Oregon Hlth Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA
[2] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA
[3] Interneuron Pharmaceut Inc, Lexington, MA USA
关键词
D O I
10.1212/WNL.57.9.1595
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Citicoline may reduce CNS ischemic injury by stabilizing cell membranes and reducing free radical generation. Previous safety and efficacy trials in patients who have had acute strokes suggested that citicoline may improve neurologic outcome with minimal side effects. Objective: To determine the safety and efficacy of citicoline treatment in acute stroke patients. Methods: An 118-center, randomized, double-blind, efficacy trial in 899 patients compared placebo (n = 446) with citicoline (n = 453) (1000 mg PO twice a day) for 6 weeks, with a 6-week post-treatment follow-up period. Patients with acute (less than or equal to 24 hours) ischemic strokes clinically thought to be in the middle cerebral artery territory with NIH Stroke Scale (NIHSS) scores greater than or equal to8 were enrolled. Results: Mean time to treatment was 13 hours for both groups and mean age was 67 years for those receiving placebo and 68 years for those receiving citicoline. Mean baseline NIHSS scores were 14.5 for placebo and 13.9 for citicoline (p = 0.06); medians were 14 for placebo and 13 for citicoline (p = 0.04). The incidence and type of side effects were similar between the groups. There were no between-group differences on the planned primary analysis, percent of patients with a greater than or equal to7-point NIHSS score change at 90 days (placebo 51%, citicoline 52%). There were no between-group differences on the other planned secondary analyses at 90 days, including mortality. However, post hoc analyses using standard "excellent recovery" measures suggested a possible treatment effect on the modified Rankin 0 or 1 (last observation carried forward: placebo 20%, citicoline 26%; p = 0.025) as well as a global outcome statistic. Conclusions: Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses. Post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.
引用
收藏
页码:1595 / 1602
页数:8
相关论文
共 50 条
  • [1] A randomized efficacy trial of citicoline in patients with acute ischemic stroke
    Clark, WM
    Williams, BJ
    Selzer, KA
    Zweifler, RM
    Sabounjian, LA
    Gammans, RE
    STROKE, 1999, 30 (12) : 2592 - 2597
  • [2] Randomized efficacy trial of citicoline in acute ischemic stroke
    Clark, WM
    Williams, J
    Selzer, KA
    Zweifler, RM
    Sabounjian, LA
    STROKE, 1998, 29 (01) : 287 - 287
  • [3] Citicoline in acute ischemic stroke: A randomized controlled trial
    Agarwal, Ayush
    Vishnu, Venugopalan Y.
    Sharma, Jyoti
    Bhatia, Rohit
    Garg, Ajay
    Dwivedi, Sadanand
    Upadhyay, Ashish
    Goyal, Vinay
    Singh, Mamta Bhushan
    Gupta, Anu
    Rajan, Roopa
    Srivastava, M. V. Padma
    PLOS ONE, 2022, 17 (05):
  • [4] Randomized dose response trial of citicoline in acute ischemic stroke patients
    Clark, WM
    Warach, SJ
    NEUROLOGY, 1996, 46 (02) : 62004 - 62004
  • [5] A randomized dose-response trial of citicoline in acute ischemic stroke patients
    Clark, WM
    Warach, SJ
    Pettigrew, LC
    Gammans, RE
    Sabounjian, LA
    NEUROLOGY, 1997, 49 (03) : 671 - 678
  • [6] A randomized trial on the efficacy of intensive rehabilitation in the acute phase of ischemic stroke
    Andrea Di Lauro
    Lorenzo Pellegrino
    Giuseppe Savastano
    Clemente Ferraro
    Michele Fusco
    Francesco Balzarano
    Mirella Marina Franco
    Luciano Gaetano Biancardi
    Alberto Grasso
    Journal of Neurology, 2003, 250 : 1206 - 1208
  • [7] A randomized trial on the efficacy of intensive rehabilitation in the acute phase of ischemic stroke
    Di Lauro, A
    Pellegrino, L
    Savastano, G
    Ferraro, C
    Fusco, M
    Balzarano, F
    Franco, MM
    Biancardi, LG
    Grasso, A
    JOURNAL OF NEUROLOGY, 2003, 250 (10) : 1206 - 1208
  • [8] Cervene in acute ischemic stroke: Results of a phase III randomized efficacy study
    Clark, WM
    Raps, EC
    Tong, DC
    Kelley, RE
    STROKE, 1999, 30 (01) : 234 - 234
  • [9] Trafermin in acute ischemic stroke: Results of a phase II/III randomized efficacy study
    Clark, WM
    Schim, JD
    Kasner, SE
    Victor, SJ
    NEUROLOGY, 2000, 54 (07) : A88 - A88
  • [10] Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke A Randomized Clinical Trial
    Wang, Anxin
    Jia, Baixue
    Zhang, Xuelei
    Huo, Xiaochuan
    Chen, Jianhuang
    Gui, Liqiang
    Cai, Yefeng
    Guo, Zaiyu
    Han, Yuqing
    Peng, Zhaolong
    Jing, Ping
    Chen, Yongjun
    Liu, Yan
    Yang, Yong
    Wang, Fengyun
    Sun, Zengqiang
    Li, Tong
    Sun, Hongxia
    Yuan, Haicheng
    Shao, Hongmin
    Gao, Lianbo
    Zhang, Peipei
    Wang, Feng
    Cao, Xiangyang
    Shi, Wanchao
    Li, Changmao
    Yang, Jianwen
    Zhang, Hong
    Wang, Feng
    Deng, Jianzhong
    Liu, Yanjie
    Deng, Weisheng
    Song, Cunfeng
    Chen, Huisheng
    He, Li
    Zhao, Hongdong
    Li, Xianfeng
    Yang, Hong
    Zhou, Zhiming
    Wang, Yilong
    Miao, Zhongrong
    JAMA NEUROLOGY, 2023, 80 (08) : 851 - 859